Showing results (11-20 of 31) with videos related to
Sort By:
Pageof 4
Oncoimmunology|December 22, 2016
Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumorValentino Le Noci, Michele Sommariva, Monica Tortoreto, et al.Breast Cancer Research and Treatment|December 7, 2007
Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signalingNicola Normanno, Manuela Campiglio, Monica R Maiello, et al.Journal of Cellular Physiology|November 7, 2003
Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression levelManuela Campiglio, Alberta Locatelli, Clelia Olgiati, et al.Proceedings of the National Academy of Sciences of the United States of America|December 5, 2006
FHIT-proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cellsFrancesca Bianchi, Alessandra Magnifico, Clelia Olgiati, et al.Cells|February 23, 2019
Wound Healing Fluid Reflects the Inflammatory Nature and Aggressiveness of Breast TumorsRoberto Agresti, Tiziana Triulzi, Marianna Sasso, et al.Journal of Cellular Physiology|January 19, 2006
The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinibNicola Normanno, Antonella De Luca, Monica R Maiello, et al.Journal of Cellular Physiology|February 26, 2015
Fhit Nuclear Import Following EGF Stimulation Sustains Proliferation of Breast Cancer CellsFrancesca Bianchi, Marianna Sasso, Federica Turdo, et al.Cells|February 20, 2020
Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab TreatmentIlona Rybinska, Marco Sandri, Francesca Bianchi, et al.Lancet (London, England)|August 23, 2003
Role of HER2 in wound-induced breast carcinoma proliferationElda Tagliabue, Roberto Agresti, Maria Luisa Carcangiu, et al.Cancers|September 27, 2014
Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimensAntonia Martinetti, Rosalba Miceli, Elisa Sottotetti, et al.Pageof 4